2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Imaging, Emerging Technologies, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Natural Killer (NK) Cell Therapies, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Adverse Events, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Patient Safety, Diseases, Immunology, Autoimmune Disorders, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Adult, Elderly, Young Adult
PAPER

4157 Trial in progress: A first-in-human, phase 1, investigator-initiated study of autologous anti-CD64 chimeric antigen receptor T cells in relapsed/refractory (R/R) acute myeloid leukemia

Mathew G. Angelos, MD, PhD, Navin Pinto, MD2, Michael Verneris, MD3, Ajay Major, MD, MBA4, Christine M. McMahon, MD5, Maria Laura Amaya, MD PhD6, Andrew Kent, MD, PhD7, Jonathan Gutman, MD8, Veena Krishnamoorthy, PhD9, Bonnie Yates, MS, CPNP-AC10, Cheri Adams, MSHS, RN, RAC11, Sanam Shahid, MD12, Daniel Pollyea, MD13, Craig Jordan, PhD14, Terry Fry, MD15, M. Eric Kohler, MD, PhD16
1 The University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
2 Children's Hospital Colorado, Aurora, Colorado, United States
3 Children's Hospital Colorado, Aurora, Colorado, United States
4 The University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
5 The University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
6 The University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
7 The University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
8 The University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
9 The University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
10 The University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
11 The University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
12 Children's Hospital Colorado, Aurora, Colorado, United States
13 The University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
14 The University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
15 Children's Hospital Colorado, Aurora, Colorado, United States
16 Children's Hospital Colorado, Aurora, Colorado, United States

Background: The combination of a hypomethylating agent (HMA) and venetoclax (Ven) has revolutionized acute myeloid leukemia (AML) treatment. However, most patients treated with HMA/Ven will relapse with a median overall survival (mOS) of less than one year. Novel therapies with alternative anti-leukemic mechanisms, particularly those designed to circumvent venetoclax resistance, are desperately needed to improve long-term outcomes.

Monocytic leukemic stem cells (m-LSCs) are a root cause of venetoclax resistance in AML. Monocytic AML comprises approximately 30-40% of new AML diagnoses and is enriched at relapse following HMA/Ven treatment due to m-LSC clonal selection. Consequently, measurable residual disease (MRD)-negative complete remission rates, duration of remission, and mOS are markedly reduced in monocytic AML as compared to non-monocytic AML treated with HMA/Ven.

CD64 is a high affinity Fc receptor restricted to granulo-monocytic hematopoietic lineages and robustly expressed on monocytic AML and m-LSCs. Importantly, CD64 expression is absent on hematopoietic stem and progenitor cells, making it an attractive target with limited hematopoietic off-tumor toxicity. Our institution has developed and validated a best-in-class anti-CD64 chimeric antigen receptor (CAR) T cell product (CART64) with high pre-clinical potency against patient-derived CD64-expressing AML cells (Simpson, ASH 2025). CART64 is a second-generation CAR consisting of a single-chain variable fragment specific to the human CD64 antigen with 4-1BB-CD3ζ intracellular signaling domains. CART64 is manufacturable at clinical scale from T cells isolated from HMA/Ven-treated AML patients, demonstrates robust anti-leukemic activity against CD64-expressing patient-derived AML cells, and clears leukemic blasts in xenogenic mouse models with durable remissions.

Study Design: This is a first-in-human, single center, phase 1, dose-escalation study at the University of Colorado (Aurora, CO) designed to determine the safety and preliminary anti-leukemic activity of autologous CART64 in adult patients with R/R AML. A maximum of 18 eligible patients will be enrolled, undergo leukapheresis, and treated with a lymphodepletion regimen (fludarabine 30mg/m2/day + cytarabine 1-2 g/m2/day, D-6-D-2) followed by a single CART64 infusion (D0). Bridging therapy with hydroxyurea will be permitted between leukapheresis and CART64 infusion. Four dose levels may be assessed, starting at 1.0 x 106 CD3+CAR+ cells/kg (DL1) through 1.0 x 107 CD3+CAR+ cells/kg (DL3) using a Bayesian Optimal Interval (BOIN) design with intra- and inter-cohort staggering and 25% target toxicity rate. Patients will be monitored through an initial dose-limiting toxicity (DLT) period from CART64 infusion through D+42.

Objectives/Endpoints: The primary objective is to identify the safety profile and maximum tolerated dose of CART64 as determined by the defined DLTs. The secondary objectives are to evaluate CART64 manufacturing feasibility and to estimate preliminary anti-leukemia responses, per ELN2022 response criteria. Integrated correlative studies will evaluate CART64 kinetics, cytokine responses (with emphasis on myeloid-associated cytokine release syndrome), marrow immunological dynamics, and patient-reported tolerability using validated patient-reported outcomes tools.

Key Eligibility: Eligible patients are adults ≥ 18 years of age with R/R (≥ 5% blasts in marrow or blood) AML consistent with FAB classification subtypes M4 (acute myelomonocytic leukemia) or M5 (acute monocytic leukemia). Patients must have received at least one prior line of anti-leukemia therapy, including at least one cycle with venetoclax. Documentation of CD64 expression on ≥ 70% myeloblasts after the most recent relapse by multiparameter flow cytometry is required. Patients must have an available donor for a rescue stem cell transplant; prior allogeneic stem cell transplant recipients (≥ 6 months from transplant), off immunosuppression, and without graft-versus-host disease are permitted.

Significance: This is the first clinical evaluation of a CD64-directed therapy against any hematological malignancy. Outcomes from this trial may establish CD64 targeting as a viable strategy for CD64+ myeloid neoplasms that fail to respond to standard therapies. Results will further provide fundamental insights into CAR T cell immunobiology in myeloid diseases, where outcomes to date have been limited.

ClinicalTrials.gov Identifier: NCT07347418

Mathew G. Angelos, MD, PhD: No relevant conflicts of interest to declare.